Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
|Articles|December 1, 2021
Daily Medication Pearl: Insulin Lispro Injection (Admelog)
Author(s)Saro Arakelians, PharmD
Admelog is indicated to improve glycemic control in type 1 and type 2 diabetes mellitus.
Advertisement
Medication Pearl of the Day: Insulin Lispro Injection (Admelog)
Indication: Admelog is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients 3 years of age and older with type 1 diabetes mellitus and adults with type 2 diabetes mellitus.
Insight:
- Dosing: Administer Admelog by subcutaneous injection within 15 minutes before or immediately after a meal.
- Dosage forms: 10 mL multiple-dose vials, 3 mL single patient use SoloStar prefilled pens.
- Adverse events: Adverse reactions associated with Admelog include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, and rash.
- Mechanism of action: Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production.
- Manufacturer: Sanofi-Aventis
Sources:
Advertisement
Related to this article
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
2
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
3
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
4
FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL
5